Journal
OCULAR IMMUNOLOGY AND INFLAMMATION
Volume 18, Issue 5, Pages 325-333Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/09273948.2010.512696
Keywords
ACAID; corneal transplantation; immune privilege
Categories
Funding
- NEI NIH HHS [R01 EY015472] Funding Source: Medline
- Grants-in-Aid for Scientific Research [23592619] Funding Source: KAKEN
Ask authors/readers for more resources
The original evidence for the existence of immunologically privileged sites in the body was based on the prolonged survival of genetically disparate transplanted tissue in the anterior chamber of the eye. The failure of the immune system to elicit an immune response in this and other such sites constitutes the hallmark of the immune privilege status. The remarkably successful field of corneal transplantation in clinical practice is undoubtedly associated with corneal immune privilege. Several investigations have addressed the regulatory mechanisms governing this phenomenon, which involves a complex interplay between multiple molecular and cellular pathways. Furthermore, the use of various transgenic mouse models has facilitated the identification of critical pathways, which upon disruption can modify the immune privileged status of the eye. Understanding these pathways not only reveals the mechanisms underlying various ocular inflammatory disease conditions, but also has clinical implications for the transplantation field and for the treatment of autoimmunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available